Efficacy of adding glutazone to the maximum dose of glibenclamide and metformin resistant on type 2 diabetic patients

To evaluate the efficacy of adding the glutazone to maximum dose of sulfonylurea and metformin in patients with poorly controlled type 2 diabetes. Ninety six patients with type 2 diabetes who had failed medical therapy with maximal-dosage of metformin and glibenclamide received glutazone. Fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C, cholesterol and HDL levels were assessed at baseline three months later. Ninety-six patients with type 2 diabetes (74 women and 22 men) with the mean age of 55.7±9.9 years were studied. Significant reduction was seen in fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C and triglyceride levels three months after adding glutazone to therapeutic regimen (p<0.0005). There was not a significant rise in cholesterol and HDL levels before and after the new therapy. The results show that the combination of glutazone, metformin and glibenclamide may result in better control of glycemic status in diabetic patients resistant to oral first-line agents.